Advanced Glycation End Products and Psoriasis
Advanced glycation end products (AGEs) are biologically active compounds formed physiologically throughout a sequence of chemical reactions, to generate highly oxidant-reactive aldehydes that combine covalently to proteins. They accumulate slowly in tissues during ageing but also in metabolic and se...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-03-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/11/3/617 |
| _version_ | 1797608688517644288 |
|---|---|
| author | Martina Maurelli Paolo Gisondi Giampiero Girolomoni |
| author_facet | Martina Maurelli Paolo Gisondi Giampiero Girolomoni |
| author_sort | Martina Maurelli |
| collection | DOAJ |
| description | Advanced glycation end products (AGEs) are biologically active compounds formed physiologically throughout a sequence of chemical reactions, to generate highly oxidant-reactive aldehydes that combine covalently to proteins. They accumulate slowly in tissues during ageing but also in metabolic and selected inflammatory disorders. Accumulation of AGEs occurs more rapidly and intensely in the skin and serum of patients with type 2 diabetes, obesity, cardiovascular diseases, chronic renal insufficiency, and non-alcoholic fatty liver disease and also in the skin of patients with psoriasis. All of the above conditions are intimately associated with psoriasis. Interaction of AGEs with their receptors (RAGEs) stimulates cellular signaling with the formation of reactive oxygen species and activation of nuclear factor kappa light chain enhancer of activated B (NF-kB), which is a key regulator in the expression of inflammatory mediators and the production of oxidative stress. Thus, AGEs may play an interesting pathogenic role in the intersection of inflammatory and metabolic diseases, may represent a biomarker of inflammation and a potential target for novel therapeutic strategies. This is a narrative review with the objective to summarize current evidence on the role of AGEs in psoriasis. |
| first_indexed | 2024-03-11T05:48:03Z |
| format | Article |
| id | doaj.art-5f1498ce98bf436ca62b8c2a27913f62 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-11T05:48:03Z |
| publishDate | 2023-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-5f1498ce98bf436ca62b8c2a27913f622023-11-17T14:18:35ZengMDPI AGVaccines2076-393X2023-03-0111361710.3390/vaccines11030617Advanced Glycation End Products and PsoriasisMartina Maurelli0Paolo Gisondi1Giampiero Girolomoni2Section of Dermatology and Venereology, Department of Medicine, University of Verona, 37126 Verona, ItalySection of Dermatology and Venereology, Department of Medicine, University of Verona, 37126 Verona, ItalySection of Dermatology and Venereology, Department of Medicine, University of Verona, 37126 Verona, ItalyAdvanced glycation end products (AGEs) are biologically active compounds formed physiologically throughout a sequence of chemical reactions, to generate highly oxidant-reactive aldehydes that combine covalently to proteins. They accumulate slowly in tissues during ageing but also in metabolic and selected inflammatory disorders. Accumulation of AGEs occurs more rapidly and intensely in the skin and serum of patients with type 2 diabetes, obesity, cardiovascular diseases, chronic renal insufficiency, and non-alcoholic fatty liver disease and also in the skin of patients with psoriasis. All of the above conditions are intimately associated with psoriasis. Interaction of AGEs with their receptors (RAGEs) stimulates cellular signaling with the formation of reactive oxygen species and activation of nuclear factor kappa light chain enhancer of activated B (NF-kB), which is a key regulator in the expression of inflammatory mediators and the production of oxidative stress. Thus, AGEs may play an interesting pathogenic role in the intersection of inflammatory and metabolic diseases, may represent a biomarker of inflammation and a potential target for novel therapeutic strategies. This is a narrative review with the objective to summarize current evidence on the role of AGEs in psoriasis.https://www.mdpi.com/2076-393X/11/3/617psoriasisadvanced glycation end productsAGEsinflammationautoimmunity |
| spellingShingle | Martina Maurelli Paolo Gisondi Giampiero Girolomoni Advanced Glycation End Products and Psoriasis Vaccines psoriasis advanced glycation end products AGEs inflammation autoimmunity |
| title | Advanced Glycation End Products and Psoriasis |
| title_full | Advanced Glycation End Products and Psoriasis |
| title_fullStr | Advanced Glycation End Products and Psoriasis |
| title_full_unstemmed | Advanced Glycation End Products and Psoriasis |
| title_short | Advanced Glycation End Products and Psoriasis |
| title_sort | advanced glycation end products and psoriasis |
| topic | psoriasis advanced glycation end products AGEs inflammation autoimmunity |
| url | https://www.mdpi.com/2076-393X/11/3/617 |
| work_keys_str_mv | AT martinamaurelli advancedglycationendproductsandpsoriasis AT paologisondi advancedglycationendproductsandpsoriasis AT giampierogirolomoni advancedglycationendproductsandpsoriasis |